Base de dados : MEDLINE
Pesquisa : D08.244.453.487 [Categoria DeCS]
Referências encontradas : 3 [refinar]
Mostrando: 1 .. 3   no formato [Detalhado]

página 1 de 1

  1 / 3 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28166973
[Au] Autor:Songsasen N; Thongkittidilok C; Yamamizu K; Wildt DE; Comizzoli P
[Ad] Endereço:Center for Species Survival, Smithsonian Conservation Biology Institute, National Zoological Park, Front Royal, VA, 22630, USA. Electronic address: songsasenn@si.edu.
[Ti] Título:Short-term hypertonic exposure enhances in vitro follicle growth and meiotic competence of enclosed oocytes while modestly affecting mRNA expression of aquaporin and steroidogenic genes in the domestic cat model.
[So] Source:Theriogenology;90:228-236, 2017 Mar 01.
[Is] ISSN:1879-3231
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Using the domestic cat as a non-rodent, larger animal model, the objective was to determine the impact of a brief incubation in a hypertonic microenvironment on (1) ovarian follicle and oocyte growth in vitro, (2) developmental capacity of the resident oocyte, and (3) expression of aquaporin (AQP) genes in parallel with genes involved in regulation of folliculogenesis. In Study 1: Secondary or early antral follicles encapsulated in 0.5% alginate were allocated to one of three treatment groups: 1) culture in standard medium at 290 mOsm for 15 d (Control); 2) incubation in 350 mOsm medium for 1 h followed by culture in standard medium for 15 d (Hypertonic-1h); or 3) incubation in 350 mOsm medium for 24 h followed by incubation in standard medium for additional 14 d (Hypertonic-24h). After measuring follicle and oocyte diameters on Day 15, in vitro-grown oocytes were incubated for 24 h before assessing nuclear status. In Study 2: secondary or early antral follicles were subjected to one of the three treatments: 1) culture in standard medium at 290 mOsm for 48 h; 2) incubation in 350 mOsm medium for 1 h followed by culture in standard medium for additional 47 h; or 3) incubation in 350 mOsm medium for 24 h followed by culture in standard medium for additional 24 h. At the end of the culture period, all follicles were assessed for mRNA level of Cyp17a1, Cyp19a1, Star, Aqp1, 3, 5, 7 and 8 as well as Fshr using qPCR. Freshly collected follicles also were subjected to gene expression analysis and served as the 'Non-cultured control'. Hypertonic-24h follicles grew larger (P < 0.05) than the control, whereas those in Hypertonic-1h group exhibited intermediate growth, especially when the culture started at the early antral stage. Oocytes in the Hypertonic-24h group were larger and resumed meiosis at a higher rate than in the other treatments. In vitro culture affected (P < 0.05) mRNA expression of Cyp19a1, Star, Aqp1, and Aqp7 in both the secondary and early antral stage while Fshr was only affected in the former compared to the non-cultured control. Pre-incubating follicles in 350 mOsm medium for 24 h enhanced (P < 0.05) Star and Aqp7 while decreasing (P < 0.05) Aqp1 expression compared to the control in secondary follicles, but not in the early antral stage. In summary, short-term hypertonic exposure promoted cat follicle development in vitro (including the meiotic competence of the enclosed oocyte) possibly through a mechanism that does not involve water transport genes.
[Mh] Termos MeSH primário: Aquaporinas/metabolismo
Aromatase/metabolismo
Família 17 do Citocromo P450/metabolismo
Soluções Hipertônicas/farmacologia
Oócitos/efeitos dos fármacos
Folículo Ovariano/efeitos dos fármacos
Folículo Ovariano/crescimento & desenvolvimento
Receptores do FSH/metabolismo
[Mh] Termos MeSH secundário: Animais
Aquaporinas/genética
Aromatase/genética
Gatos
Técnicas de Cultura de Células/veterinária
Família 17 do Citocromo P450/genética
Feminino
Expressão Gênica
Oócitos/crescimento & desenvolvimento
Oócitos/metabolismo
RNA Mensageiro/metabolismo
Receptores do FSH/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aquaporins); 0 (Hypertonic Solutions); 0 (RNA, Messenger); 0 (Receptors, FSH); EC 1.14.14.1 (Aromatase); EC 4.1.2.30 (Cytochrome P450 Family 17)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170208
[St] Status:MEDLINE


  2 / 3 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26637407
[Au] Autor:Moore DC; Moore A
[Ad] Endereço:Southeast Missouri Hospital, Cape Girardeau, MO, USA.
[Ti] Título:Abiraterone-induced rhabdomyolysis: A case report.
[So] Source:J Oncol Pharm Pract;23(2):148-151, 2017 Mar.
[Is] ISSN:1477-092X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Abiraterone is an inhibitor of androgen biosynthesis indicated for the treatment of metastatic castration-resistant prostate cancer. Common side effects include diarrhea, edema, hypokalemia, hypertension, and liver function test abnormalities. We report a case of rhabdomyolysis developing in association with the use of abiraterone. Following discontinuation of abiraterone, creatine kinase concentrations decreased gradually throughout the duration of the hospitalization.
[Mh] Termos MeSH primário: Analgésicos Opioides/efeitos adversos
Androstenos/efeitos adversos
Constipação Intestinal/induzido quimicamente
Morfina/efeitos adversos
Neoplasias de Próstata Resistentes à Castração/tratamento farmacológico
Rabdomiólise/induzido quimicamente
[Mh] Termos MeSH secundário: Analgésicos Opioides/administração & dosagem
Analgésicos Opioides/uso terapêutico
Androstenos/uso terapêutico
Antineoplásicos Hormonais/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica
Constipação Intestinal/complicações
Creatina Quinase/sangue
Família 17 do Citocromo P450/antagonistas & inibidores
Quimioterapia Combinada
Seres Humanos
Injeções Espinhais
Masculino
Meia-Idade
Morfina/administração & dosagem
Morfina/uso terapêutico
Náusea/etiologia
Manejo da Dor/métodos
Prednisona/uso terapêutico
Rabdomiólise/sangue
Vômito/etiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Analgesics, Opioid); 0 (Androstenes); 0 (Antineoplastic Agents, Hormonal); 76I7G6D29C (Morphine); EC 2.7.3.2 (Creatine Kinase); EC 4.1.2.30 (Cytochrome P450 Family 17); G819A456D0 (abiraterone); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170606
[Lr] Data última revisão:
170606
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151206
[St] Status:MEDLINE
[do] DOI:10.1177/1078155215620921


  3 / 3 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26995740
[Au] Autor:Guang-Yu L; Hai-Yan L; Ji-Hong L; Yun-Cong M; Xue-Lian D; Chun-Yu L; Wen-Yong S
[Ad] Endereço:First Affiliated Hospital of Guangxi Medical University, Guangxi, P. R. China.
[Ti] Título:MCL1 is a key regulator of steroidogenesis in mouse Leydig cells.
[So] Source:Mol Reprod Dev;83(3):226-35, 2016 Mar.
[Is] ISSN:1098-2795
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Myeloid cell leukemia-1 (MCL1), an anti-apoptotic member of the BCL2 family, is expressed abundantly in the testis. Previous characterization revealed that MCL1 is expressed exclusively in the Leydig cells in the mouse testis, yet what it does in these cells remains unknown. We therefore analyzed testosterone biosynthesis in isolated primary Leydig cells and the MA-10 cell line, in which MCL1 was knocked down using an siRNA strategy. The mRNA abundance of the steroidogenic genes Star, Cyp11a1, Cyp17a1, Hsd3b1, Srd5a, and the luteinizing hormone/choriogonadotropin receptor Lhcgr were significantly reduced following MCL1 knockdown. Of the two enzymes required for testosterone biosynthesis, STAR and P450 SCC (encoded by Cyp11a1) enzyme abundance was also reduced following Mcl1 siRNA treatment, possibly leading to the reduced production of sex steroid precursors, and testosterone in these knockdown cells. Despite its classification as an anti-apoptosis protein, Mcl1 siRNA treatment did not affect cell survival. Collectively, our findings indicate that MCL1 plays a pivotal role in Leydig-cell steroidogenesis, and might provide novel insights into metabolic regulation in this cell. Mol. Reprod. Dev. 83: 226-235, 2016. © 2016 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Proteína de Sequência 1 de Leucemia de Células Mieloides/metabolismo
Esteroides/metabolismo
[Mh] Termos MeSH secundário: 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/genética
3-Oxo-5-alfa-Esteroide 4-Desidrogenase/metabolismo
Animais
Linhagem Celular
Sobrevivência Celular
Enzima de Clivagem da Cadeia Lateral do Colesterol/genética
Enzima de Clivagem da Cadeia Lateral do Colesterol/metabolismo
Família 17 do Citocromo P450/genética
Família 17 do Citocromo P450/metabolismo
Células Intersticiais do Testículo
Masculino
Proteínas de Membrana/genética
Proteínas de Membrana/metabolismo
Camundongos
Complexos Multienzimáticos/genética
Complexos Multienzimáticos/metabolismo
Proteína de Sequência 1 de Leucemia de Células Mieloides/genética
Fosfoproteínas/genética
Fosfoproteínas/metabolismo
Progesterona Redutase/genética
Progesterona Redutase/metabolismo
Receptores do LH/genética
Receptores do LH/metabolismo
Esteroide Isomerases/genética
Esteroide Isomerases/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase); 0 (Mcl1 protein, mouse); 0 (Membrane Proteins); 0 (Multienzyme Complexes); 0 (Myeloid Cell Leukemia Sequence 1 Protein); 0 (Phosphoproteins); 0 (Receptors, LH); 0 (Steroids); 0 (steroidogenic acute regulatory protein); EC 1.1.1.145 (Progesterone Reductase); EC 1.14.15.6 (Cholesterol Side-Chain Cleavage Enzyme); EC 1.3.99.5 (3-Oxo-5-alpha-Steroid 4-Dehydrogenase); EC 1.3.99.5 (Srd5a1 protein, mouse); EC 4.1.2.30 (Cytochrome P450 Family 17); EC 5.3.3.- (Steroid Isomerases)
[Em] Mês de entrada:1612
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160321
[St] Status:MEDLINE
[do] DOI:10.1002/mrd.22614



página 1 de 1
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde